The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The MOST study: differences in disease progression amongst patients with low-risk MF
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, comments on the Myelofibrosis and Essential Thrombocythemia Observational Study (MOST; NCT02953704), which aimed to investigate the spectrum of disease within myeloproliferative neoplasms (MPNs), specifically focusing on the transition of patients between low-risk myelofibrosis (MF) and essential thrombocythemia (ET). The study’s findings elucidated that some patients with low-risk MF progress to a higher-risk disease state much more rapidly than others, indicating two distinct trajectories of the disease. Dr Gerds highlights the need to observe the molecular mechanisms responsible for the varying rates of progression to better understand the drivers of the disease. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AbbVie, Bristol Myers Squibb, Constellation Pharmaceuticals, GlaxoSmithKline, Kartos, Novartis, PharmaEssentia, Sierra Oncology
Research Funding: Accurate Pharmaceuticals, Constellation Pharmaceuticals, CTI BioPharma, Imago BioSciences, Incyte Corporation, Kratos Pharmaceuticals
